Ricevi le ultime notizie sulle azioni Kazia Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di KZIA

Ultime notizie per

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

News

Press Releases

Peraso Inc. (NASDAQ: PRSO): The Only Pure-Play mmWave Stock Poised for Growth – More Stocks Inside

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Small Cap

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Opinion

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

Contracts

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

AMZN

ATHE

BNZI

CLDI

COST

HSDT

IMNN

IMRX

INEO

KBSX

KZIA

NUVB

ONCY

PNPNF

PRSO

SNYR

TRNR

TSX:ONC

TSXV:PNPN

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Generation Bio

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma Co

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PepGen

Pluri

RenovoRx

Senti Biosciences

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Exicure

X4 Pharmaceuticals

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

HC Wainwright & Co.

Maxim Group

Comments

Kazia Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO